Concepedia

Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes

Hans Richter, G. Martin Benson, Denise Blum, Evelyne Chaput, Song Feng, Christophe Gardès, Uwe Grether, Peter Hartman, Bernd Kuhn, Rainer E. Martin,

Bioorganic & Medicinal Chemistry Letters · 2010 · 57 citations · 8 references

DOIFull text

Open access

Concepts

References

8

6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity

Roberto Pellicciari, Stefano Fiorucci, Emidio Camaioni et al. · Journal of Medicinal Chemistry · 2002 · 731 citations · Full text

, , +12

The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice

Bertrand Cariou, Kirsten van Harmelen, Daniel Durán-Sandoval et al. · Journal of Biological Chemistry · 2006 · 541 citations · Full text

, , +17

Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR

Patrick Maloney, Derek J. Parks, Curt D. Haffner et al. · Journal of Medicinal Chemistry · 2000 · 524 citations · Full text

, , +14

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

Brenton Flatt, Richard Martin, Tielin Wang et al. · Journal of Medicinal Chemistry · 2009 · 161 citations · Full text

, , +17

Development of a Scintillation Proximity Assay for Peroxisome Proliferator-Activated Receptor γ Ligand Binding Domain

James S. Nichols, Derek J. Parks, Thomas G. Consler et al. · Analytical Biochemistry · 1998 · 111 citations

, , +8